Peptide news
Curated weekly from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical takeaways for users, not academic abstracts.
- Regulatoryhcplive.com
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
TRIUMPH-1 reports that Eli Lilly's investigational GLP-1/GIP/glucagon triple agonist retatrutide reduced weight and BMI in people with obesity or overweight. The fragment does not give dose, duration, or percent weight loss, so do not compare it directly with semaglutide or tirzepatide yet. Watch for the full TRIUMPH-1 data, especially dosing, side effects, and real weight loss numbers.
Read source → - Regulatorystatnews.com
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT flags newer GLP-1 work, including triple hormone receptor drugs and a monthly obesity drug, alongside pushback on research cuts and a protest. For you, the signal is broader receptor targeting and less frequent dosing, but this fragment does not include trial data. Watch for actual human data and dosing details before treating monthly GLP-1 claims as actionable.
Read source → - Regulatorystatnews.com
The hidden history of BPC-157, a favorite MAHA peptide
STAT traces BPC-157 from Predrag Sikiric’s research into its current gray market use by bodybuilders and biohackers. The FDA approval debate matters because popularity is running ahead of clear regulatory status. If you use BPC-157, watch FDA movement and treat seller claims as unproven.
Read source → - Trialsinvestor.lilly.com
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company
Lilly says retatrutide, a triple agonist for obesity, produced strong weight loss in a Phase 3 trial, but the available text does not include the actual weight loss, dose, or safety data. Treat this as a watch item, not a reason to change anything yet. If you use or track GLP-1 style therapies, wait for the full Phase 3 data before comparing retatrutide with tirzepatide or changing your stack.
Read source → - Trialsajmc.com
Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
Retatrutide posted up to 30.3% average weight loss in Phase 3 TRIUMPH-1, extending the pattern seen in earlier smaller studies. If you are tracking weight loss peptides, watch for the full TRIUMPH-1 data before comparing it against current GLP-1 options.
Read source → - Trialsbiopharmadive.com
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
Survodutide, Boehringer’s dual action obesity injection, met its goal in a Phase 3 trial and showed Wegovy like weight loss. The muscle mass signal matters because lean mass loss is a real concern with GLP-1 based weight loss. Watch for the full Phase 3 body composition data before you treat it as interchangeable with semaglutide.
Read source → - Regulatorybiopharmadive.com
FDA moves toward easing restrictions on certain peptides
The FDA is moving toward easing restrictions on certain peptides by holding an advisory committee meeting on the topic. The move follows public comments from HHS Secretary Robert F. Kennedy Jr., so you should treat this as an active policy review, not a settled change. Watch for FDA meeting materials before changing where you source peptides.
Read source → - Regulatoryfiercepharma.com
UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
The FDA reclassified 12 unapproved peptides ahead of an advisory committee meeting on their potential use in compounded drugs. If you use compounded peptides, watch the committee outcome and ask your provider whether any peptide you buy is affected by the FDA update.
Read source → - Regulatorystatnews.com
My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
The piece argues that interest in peptides like BPC-157 is being used to replace proven care, even when evidence is thin compared with drugs like statins. If you are considering a peptide instead of a standard therapy, ask your clinician what outcomes data support that choice and do not swap a proven medication without a clear plan.
Read source → - Regulatoryinvestor.lilly.com
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Lilly says the FDA approved Foundayo™ (orforglipron), a GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. If you use or are considering a GLP-1, watch whether your provider adds Foundayo™ as an oral option, and confirm the exact dosing instructions before switching from injections.
Read source → - Regulatoryfiercepharma.com
Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo
Lilly’s orforglipron won FDA approval as Foundayo for obesity, ending Novo Nordisk’s short run as the only approved oral GLP 1 option with Wegovy pill. For you, this means oral incretin drugs are now a real category to compare with injections, not just pipeline talk. Watch how Foundayo is priced and prescribed before assuming it fits better than injectable options.
Read source → - Regulatorynejm.org
GLP-1 Receptor Agonists
GLP-1 receptor agonists are incretin analogues that help glucose trigger insulin release. If you use or compare GLP-1 therapy, watch whether your source, dose plan, and monitoring are tied to a real clinical plan.
Read source →
Pepdex aggregates research news from primary sources only, FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted outlets (BioPharma Dive, STAT, AJMC, university research pages). We summarize in plain English; you click the source link to verify. No vendor sponsorship.